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A B S T R A C T
Human biomonitoring (HBM) data can provide insight into co-exposure patterns resulting from exposure to
multiple chemicals from various sources and over time. Therefore, such data are particularly valuable for as-
sessing potential risks from combined exposure to multiple chemicals.
One way to interpret HBM data is establishing safe levels in blood or urine, called Biomonitoring Equivalents
(BE) or HBM health based guidance values (HBM-HBGV). These can be derived by converting established ex-
ternal reference values, such as tolerable daily intake (TDI) values. HBM-HBGV or BE values are so far agreed
only for a very limited number of chemicals. These values can be established using physiologically based kinetic
(PBK) modelling, usually requiring substance specific models and the collection of many input parameters which
are often not available or difficult to find in the literature.
The aim of this study was to investigate the suitability and limitations of generic PBK models in deriving BE
values for several compounds with a view to facilitating the use of HBM data in the assessment of chemical
mixtures at a screening level. The focus was on testing the methodology with two generic models, the
IndusChemFate tool and High-Throughput Toxicokinetics package, for two different classes of compounds,
phenols and phthalates. HBM data on Danish children and on Norwegian mothers and children were used to
evaluate the quality of the predictions and to illustrate, by means of a case study, the overall approach of
applying PBK models to chemical classes with HBM data in the context of chemical mixture risk assessment.
Application of PBK models provides a better understanding and interpretation of HBM data. However, the
study shows that establishing safety threshold levels in urine is a difficult and complex task. The approach might
be more straightforward for more persistent chemicals that are analysed as parent compounds in blood but high
uncertainties have to be considered around simulated metabolite concentrations in urine. Refining the models
may reduce these uncertainties and improve predictions. Based on the experience gained with this study, the
performance of the models for other chemicals could be investigated, to improve the accuracy of the simulations.
1. Introduction
Human biomonitoring (HBM) allows assessment of exposure to
chemicals by measuring these compounds, their metabolites or other
biomarkers of exposure present in body fluids (blood, urine, saliva,
breast milk) or other biological matrices (hair, nails and teeth). In
addition, monitoring of indoor and outdoor media (air and dust), and
chemical exposure associated with food intake via diet diaries can be
collected together with information on study participants' age, sex,
socioeconomic background to give a more complete picture of external
and internal exposure and to link human exposure to exposure sources
and epidemiological survey data.
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HBM programmes have been developed for decades. One example is
the American HBM programme (National Health and Nutrition
Examination Survey, NHANES), the largest ongoing project running
since 1971 (McDowell, 1971). In Europe, various projects have been
carried out over the years (Choi et al., 2015). In the Democophes pro-
ject, mother–child pairs over large parts of Europe were studied (Den
Hond et al., 2015) and in 2017 a project was launched by the European
Commission called “The European Human Biomonitoring Initiative”
(HBM4EU) which is a joint effort of 30 European countries. The aim of
the project is to collect and interpret HBM data throughout Europe in
order to safely manage chemicals and protect human health (HBM4EU,
2019). The long-term goal is to build bridges between the research and
policy worlds and deliver benefits to society in terms of enhanced
chemical safety.
Interpretation of HBM data is particularly valuable in the context of
assessing combined exposure to multiple chemicals. The environment
we live in is made up of an assortment of chemicals, some of which are
potentially harmful if ingested in certain concentrations or combined
with other chemicals. HBM data provide a measure of internal co-ex-
posure to multiple chemicals and aggregate exposure to single chemi-
cals across routes and sources of exposure.
The best way to interpret chemical concentration data is to compare
them to a concentration that is deemed safe. Currently, the majority of
these safe values are established as an intake dose, known as an ac-
ceptable or tolerable daily intake (ADI or TDI) or reference dose (RfD),
referring to how much of one chemical a person can ingest daily over a
lifetime without diminishing their health (FAO and WHO, 2009). Only
recently have studies begun to look into establishing safe levels in urine
or blood against which measured values can be compared. These are
known as Biomonitoring Equivalents (BE) or HBM health based gui-
dance values (HBM HBGV) (Angerer et al., 2011). Such reference values
can serve as first screening values to evaluate potential risks based on
chemical concentrations measured in biological samples such as human
blood or urine, for individual chemicals and eventually also for com-
binations of multiple chemicals.
Some of the existing BE values have been related to biomonitoring
data with the use of physiologically based kinetic (PBK)3 models (WHO,
2015), such as the one shown in Fig. 1. These models are based on
mathematical descriptions of physiological characteristics (tissue vo-
lumes, blood flow, etc.) and biochemical processes (Vmax, Km, etc.)
(Krishnan et al., 1994). PBK models describe the body as a set of in-
terconnected compartments, which represent the organs and blood,
describing the absorption, distribution, metabolism, and excretion
(ADME) properties of a chemical or drug within the body (Krishnan and
Andersen, 2007). For a given exposure scenario, PBK models predict the
time-course of a parent chemical, its metabolite(s) or biomarkers of
exposure as target tissue concentrations in an organism. PBK models
can be used in two ways, either via forward dosimetry or reverse do-
simetry (Hays et al., 2007). The former uses an intake dose and esti-
mates the concentration of a compound in human fluids, whilst the
latter uses the measured concentration in a body fluid and identifies the
dose the person was exposed to. Either way, results from PBK models
can be used to refine the setting of safe levels. In addition, PBK models
can also be used to compare subgroups (sex, age, and sensitive popu-
lation), characterise inter-individual variation, perform a range of ex-
trapolations (e.g. acute to chronic exposure, route to route, low to high
doses), and support read-across between substances by comparing ki-
netic profiles of structurally similar substances.
PBK models can be chemical specific or generic. A chemical specific
PBK model is built using knowledge of the physicochemical / ADME
properties and Mode of Action (MoA) for the specific chemical under
study. For instance, distribution to relevant target organs and specific
metabolite formation should be measured and included (Kawai et al.,
1994; Abbiati and Manca, 2017; Hoffman and Hanneman, 2017; Moss
et al., 2017). On the other hand, a more generic PBK model has a de-
fined compartmental structure for all chemicals tested. These models
are usually built on IT platforms (see Madden et al., 2019 for an
overview of such platforms). This allows computing an entire chemical
list with the same type of input data and the same assumptions and
limitations. Furthermore the simulation of more than one chemical can
be carried out at once and hence simplifies the task of carrying out a
mixture risk assessment (Desalegn et al., 2018).
In a recent survey on the use of HBM data in chemical risk assess-
ments, the lack of HBM guidance values was identified as an obstacle
(Louro et al., 2019). The objective of our investigation was therefore to
examine the suitability of using generic PBK models for deriving BE
values based on TDIs or RfDs that can then be used for mixture risk
assessment using HBM data at a screening level. The suitability of
generic PBK models was investigated since it is very resource intensive
to build specific PBK models for each single chemical and to derive their
input parameters. In addition, the application of generic PBK models
made it possible to compare multiple chemicals in a more homogenous
way.
Several exposure platforms and models are currently available for
analysis of HBM data, e.g. Stochastic Human Exposure and Dose
Simulation (SHEDS) model, ConsEXPO, EUSES, Integra,
IndusChemFate, HBM Simulator, MerlinExpo, and R/Httk. The aim of
this study was to use generic PBK model platforms, which were chosen
based on the following criteria: easy to use, readily available, full
documentation and manual of use, transparent and simple, and easy to
manipulate in case minor amendments were needed. For this purpose,
five of these platform/models (Integra, IndusChemFate, HBM
Simulator, MerlinExpo, R/Httk) were screened to match with inclusion
exclusion criteria (supplementary material section S2 and Table S2).
Based on this analysis and the criteria listed above, two generic tools
were considered in this project, the IndusChemFate (ICF) tool and the
High-Throughput Toxicokinetics (Httk) package, which are further
described in Section 2.2. The correct mathematical implementation of
the model structures were also verified by examining available details
of the differential equations used (and/or the availability of the math-
ematical model code) and the parameterisations of the PBK model. The
maintenance of mass-balance as well as blood flow balances within the
model should be supported; equations and parameter values should be
devoid of syntax or mathematical errors. Furthermore, it should be
ensured that there are no numerical errors (World Health Organization,
Fig. 1. Schematic representation of a PBK model.
3 The term PBK model is synonymous with physiologically based pharmaco-
kinetic (PBPK), physiologically based biokinetic (PBBK), and physiologically
based toxicokinetic (PBTK) models.
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2010). To this end the PBK model platforms were evaluated using the
criteria laydown by WHO (2010) and by OECD (Sachana, 2019, OECD,
2020) and results reported in Supplementary Material S4.
Both models were used in a forward-dosimetry approach with es-
tablished TDI or RfD values to obtain urinary BE concentrations, i.e.
BETDI and BERfD. Subsequently, with the information collected, a mix-
ture risk assessment was carried out using HBM data obtained in
Norwegian and Danish cohort studies (see Fig. 2). The mixture risk
assessment was done for illustration purposes showing how such data
might potentially be applied. This case study should not be regarded as
a detailed risk assessment, but as a proof of concept.
2. Methodology
The overall approach is represented in Fig. 3, which reports the
steps taken for the HBM analysis with the choice of chemicals (para-
bens, phenols, phthalates), the application of a Monte Carlo sampling
approach for generation of ‘virtual populations’ (to capture the re-
sponse for a representative population), and the steps for the illustrative
risk assessment.
2.1. Step 1: Selection of human biomonitoring data
In order to identify HBM studies covering the analysis of many
different chemicals and chemical groups per subject, we searched the
literature and the HBM module of the Information Platform for
Chemical Monitoring (IPCHEM, https://ipchem.jrc.ec.europa.eu).
Among the relevant data sets identified, two were available and kindly
provided under Data Transfer Agreements. The HBM data used in this
study were from a Norwegian and two Danish cohort population ob-
tained between January and May 2012, and between 2006 and 2007,
respectively. In the respective studies, several classes of chemicals have
been analysed, but for the study presented here, we focused on
phthalates and phenols as substance groups. For the Norwegian study,
we used the urinary concentrations and daily intakes estimated from
measurements in external sources such as food, air, and dust.
Evaluation of urinary output is most straightforward if urine col-
lection is complete (i.e., all output over periods of 24 h or more is
captured). In practice, this can be very difficult, especially in some
population groups such as children. Consequently, spot samples are
often gathered instead. Spot samples are single void urine samples,
which can be collected at any time during the day. If a single spot
sample is to be collected per day, first morning voids (FMVs) are often
selected on the basis of the assumption that the FMV provides an in-
tegrated sample over a relatively long part of the day and is therefore
more likely to be representative (Kissel et al 2005).
Changes in the volume of fluid excreted will result in variability of
urinary parent compound and metabolite concentrations irrespective of
exposure to the chemical (Pearson et al., 2009). This is usually dealt
with by standardising the measured crude concentration of the com-
pound of interest against the urine dilution expressed as either specific
gravity, osmolality or creatinine. Urinary creatinine can be used to
correct for urinary concentrations because its production and excretion
Fig. 2. Use of Tolerable Daily Intake (TDI), Reference Dose (RfD) and Estimated
Daily Intake (EDI) values as input doses in a forward dosimetry approach to
obtain BETDI, BERfD and BEEDI values for risk assessment. The derived BE values
can subsequently be compared to actual measured urinary concentrations.
Fig. 3. Workflow for the application of ICF/excel and the Httk/r, highlighting the steps used for the HBM analysis. Only Httk results were used for mixture risk
assessment (MRA). A limitation was that the metabolism could not be taken into account in the current version of the Httk/r; the version 1.8, (2018). *Chemicals
included in the analysis are: Phenols: Bisphenol A, Triclosan, Benzophenone-3; Phthalates: Di-n-butyl phthalate (DnBP), Butylbenzyl phthalate (BBzP); Parabens:
Methyl paraben, Ethyl paraben, n-Propyl paraben, n-Butyl paraben. HBM: Human biomonitoring, TDI: Tolerable daily intake, EDI: Estimated daily intake, BE:
Biomonitoring equivalent.
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are relatively constant due to homeostatic control mechanisms, and
creatinine excretion is mostly independent of urine flow (Boeniger,
Lowry, & Rosenberg, 1993). We have resolved this by using standar-
dised urinary concentrations in the Norwegian (specific gravity ad-
justed). For the Danish data sets we used unadjusted urinary con-
centrations. Lassen et al (2013) investigated the variability for repeated
measurements of BPA and seven other phenols in spot, morning and
24 h urine samples. Normalisation of concentrations to osmolality, vo-
lume and creatinine did not substantially change the intraclass corre-
lation coefficients (ICCs) for the repeated measurements.
The Norwegian dataset is based on a mother–child study cohort (48
mothers aged 32–56 years and 48 children aged 6–11 years). Urine
samples were taken from 48 mothers and 46 children as morning spot
samples (Cequier et al., 2017). Concentrations of several chemicals
were measured from each of these urine samples; 23 adult females and
28 children have missing values for single chemicals because of inter-
ferences or below limit of detection (LoD). Further details about the
enrolment, dietary intake (recording of food consumption), sample
collection, and analysis have been published elsewhere (Cequier et al.,
2015, 2017). For some compounds, also food, dust, and air samples
were analysed to determine external exposure from which estimated
daily intakes (EDIs) were calculated (Cequier et al., 2014; Sakhi et al.,
2014; Liagkouridis et al., 2017).
Specific gravity (SG) was measured in all samples and spanned from
1.003 to 1.032 (mean= 1.015) in mothers and from 1.009 to 1.032
(mean=1.024) in children. The urinary concentrations were calcu-
lated according to the equation proposed by Boeniger et al. (1993) and
using the SG values of the participants in the calculation (Cequier et al.,
2017, 2015).
One of the major limitations in working with short half-life bio-
markers is the within individual variability. In the Norwegian study, the
48 mothers collected 2–8 urine samples over a period of 24 h, and the
children collected 2–3 samples (at least morning and afternoon),
(Cequier et al., 2015). 44% of the mother participants collected all spot
urine samples, 27% participants collected more than 3 spot urine
samples and 29% collected 2–3 spot urine samples (Sakhi et al., 2017;
Sakhi et al., 2018). The calculated 24-h ICCs (as published in their
study) were moderate to high for most of the phthalates and phenols
indicating that the within individual variation is less compared to be-
tween individual variation during 24-h (Table S1.1 and S1.2).
The Danish population was made up of subsets of two cohort stu-
dies: firstly data from spot urine samples of 849 children aged
4–10 years from the Copenhagen Mother-Child Cohort (http://www.
edmarc.net/mother-child-cohort.html; Boas et al., 2010; Frederiksen
et al., 2014), secondly from 24 h urine samples of 129 children and
adolescents between 6 and 21 years of age from the Copenhagen Pub-
erty Study collected in 2007 (http://www.edmarc.net/puberty-cohort.
html; Frederiksen et al., 2011, 2013, 2014). For the purpose of our
study, only urine measurements in children aged 6–11 years were
considered in order to compare the Danish group of children to the
same age group of Norwegian children. This sub-group consists of 725
children in total (660 from the Copenhagen Mother Child cohort and 65
from the Copenhagen Puberty Study). Phthalate metabolites were
measured in both Danish cohorts, while phenols such as BPA, TCS and
BP-3 were measured in the Copenhagen Mother-Child Cohort and
parabens were measured in the Copenhagen Puberty Study. For the
Danish data sets we compared non-normalised and creatinine-adjusted
concentration measurements (Table S1.3). The variability and range of
concentrations did not change substantially after normalisation. Since
the creatinine adjusted concentrations cannot be directly compared to
the model outputs we used non-adjusted concentrations.
2.2. Step 2: Generic physiologically based kinetic model selection
A first search was conducted to find PBK model platforms of in-
terest. This search resulted in a choice between 5 different platforms:
Integra, IndusChemFate, HBM Simulator, MerlinExpo, and R/Httk. A
table (supplementary material) was designed to compare the models
and platforms. The desired platforms should be easy to use, readily
available, with full documentation and manual of use, transparent and
simple, and easy to manipulate in case minor amendments were
needed. These considerations led to the selection of the platforms ICF
and Httk for this study (details presented in Supplementary Material
S2).
2.2.1. The IndusChemFate tool
ICF was developed by IndusTox Consult & Santoxar, funded by the
Long Range Initiative (LRI) of CEFIC within the context of the HBM2
project and is freely available on the CEFIC-LRI website (Jongeneelen
and ten Berge, 2011a, 2011b). The model is built in an MS excel
spreadsheet, the source code is written in Visual Basic and is not
password protected. The model contains 11 body compartments (i.e.
lung, heart, brain, skin, adipose, muscles, bone, bone marrow, stomach
and intestines (lumped), liver, and kidney) and calculates parent
compound and one or more metabolite concentrations in organs over
time, as well as the amount excreted in urine. This allows for the study
of phthalates as they are rapidly metabolised (Frederiksen et al., 2007)
and the concentration of some of their metabolites are an adequate
indicator of exposure to the parent compound (Ramesh Kumar and
Sivaperumal, 2016). By default, the model assumes physiological and
anatomical parameters of a 70 kg reference human; however, several
different subjects (e.g. male or female adult or child, with normal
weight or obese) can be selected.
2.2.2. The High-Throughput Toxicokinetics (Httk) package
The High-Throughput Toxicokinetics (Httk) package can be found in
the CRAN r project (https://cran.r-project.org/web/packages/httk/
index.html) which was created by the U.S. EPA's National Center for
Computational Toxicology and constitutes a compilation of a one,
three, and seven-compartment PBK (physiologically based tox-
icokinetic) models intended to compute concentration vs. time curves.
A series of additional in-built functions calculate steady state con-
centrations, the number of days to reach steady state, and uncertainty
and variability using a Monte Carlo analysis. Oral - via ingestion - was
the exposure route selected to make predictions and the seven com-
partmental model was applied. All data used to parametrise the Httk
model (physiological, tissue, as well as physicochemical data sources)
are described in Pearce et al. (2017) and Wambaugh et al. (2018). In
contrast to ICF, the current version of the Httk model has no option to
simulate metabolism and consequently predict parent substance and
metabolite concentrations - only the concentration of the parent sub-
stance is predicted following metabolism, which is why the model could
not be used for phthalates. The Httk/r version used in the current study
was 1.8, (2018), the following functions were used: httkpop_generate,
get_httk_params, “solve_pbtk”, “calc_css”.
2.2.3. Sensitivity analysis on model platforms
Sensitivity analysis can broadly be described as a systematic in-
vestigation that leads to an understanding of how changes in the model
input parameters can influence the simulation outputs. The one-at-a-
time (OAT) sensitivity analysis was performed to understand to what
extent the model output is affected by changing the value of an input
parameter by 10% (increase/decrease). Sensitivity analysis should be
performed for all parameters that are likely to markedly influence the
outcome of the simulated kinetics. This includes key experimentally
determined parameters (such as Ki, Vmax, Km) and parameters with a
variety of values reported in the literature (such as kdeg).
For IndusChemFate the body and liver weight, the metabolism,
Vmax and Km were changed by 10% to understand their impact on the
model output. On the other hand, for R/httk the highest impact was
from the clearance value.
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2.3. Step 3: Selection of chemicals, their reference values, and physiological
parameters for the models
2.3.1. Step 3.1 and 3.2: Selection of chemicals and their reference values
To perform the analysis, nine compounds were selected as these
were measured in both populations (Table 1). Several other chemicals
and metabolites were available in the cohorts data sets, but were not
considered for this analysis and the mixture risk assessment (MRA) due
to limitations of both PBK models. For ICF, a steady state was not
reached for most chemicals and Httk was limited to compounds mea-
sured as parent compounds in urine as it does not include metabolism.
Four chemicals were initially selected to test the ICF model. These
chemicals were two phthalates (DnBP, BBzP) and two phenols (bi-
sphenol A, triclosan). They were chosen based on the simplicity of their
metabolism and the availability of the estimated daily intakes/tolerable
daily intakes and measured urine concentrations.
For Httk, four of the compounds under consideration were parabens
(i.e. methyl paraben, ethyl paraben, n-propyl paraben and n-butyl
paraben) and two phenols (i.e. bisphenol A and triclosan). Furthermore,
Benzophenone-3 was included in the Httk section to complete the
phenol group and therefore improve the MRA. The tolerable daily in-
takes (TDIs) established by public authorities were collected from da-
tabases or the literature and are presented in Table 1 including the
source used.
2.3.2. Step 3.3: Selection of physiological parameters for PBK modelling
2.3.2.1. IndusChemFate input parameters. For the present work, various
population scenarios were selected, e.g. normal child in rest or obese
woman doing light work. For more information on how model-inherent
parameters were defined or generated, see Jongeneelen and ten Berge
(2011a, 2011b). The duration of simulation was set for an acute oral
exposure at 24 h and for long-term exposure to steady state.
The physicochemical input parameters needed for each compound
and its metabolites include the molecular weight, density, vapour
pressure, log(octanol:water) partition coefficient at blood pH 7.4 (and
skin pH of 5.5) and water solubility. Also, the model requires estimates
of the oral absorption rate, resorption in renal tubuli, enterohepatic
removal as well as Vmax and Km values with respect to each metabolic
step that is intended to be considered.
Values of these parameters were sourced between mid July and end
of August 2018 from the U.S. EPA Chemistry Dashboard, the Agency for
Toxic Substances & Disease Registry (ATSDR), ECHA, PubChem and the
public scientific literature (Eigenberg et al., 1986; Anderson et al.,
2001; Völkel et al., 2002; Teeguarden et al., 2005; Aylward et al., 2009;
European Commission Scientific Committee on Consumer Safety
(SCCS), 2009; Coughlin, Thomas and Buckley, 2012; Hanioka et al.,
2012; Koch et al., 2012; Takahara et al., 2014; Yang et al., 2015; Ashrap
et al., 2017). Properties of the BPA glucuronide used are those saved in
the ICF model.
Based on Pelkonen et al. (1973), Hakooz et al. (2006), Barter et al.
(2007) and Zhang et al. (2015), a factor of 40mg/g was adopted to
scale Vmax values from a value established in vitro to an in vivo hepatic
drug clearance value. The absorption rate (ka) was calculated using
Winiwarter et al. (1998), model 3b, to derive the logarithm of the ef-
fective permeability (Peff) and Peters (2008) to then calculate the ka. All
parameter values used for ICF simulations are presented in the sup-
plementary material S3.
To test the ICF model, two females and two children from the
Norwegian population were selected; one of “normal” weight (Woman/
Child 1) and one “obese” (Woman/ Child 2). To categorise the body
mass index (BMI) of a child information on the age and sex are needed,
however, a BMI of 16 is a normal weight for a child under 11 regardless
of sex and a BMI of 22 is overweight or obese (CDC, 2018). Given this
information, the weights of all four individuals were input into the code
(via Developer ->VisualBasic) for the corresponding normal/obese
woman/child at rest.
2.3.2.2. Httk input parameters. Httk has a library of relevant parameters
built into the model covering many chemicals, thus being very user
friendly and limiting the time needed to gather input parameters. All
data used to parametrise the Httk model (physiological, tissue, as well
as physicochemical data sources) are described in Pearce et al. (2017)
and Wambaugh et al. (2018).
Sample size for general population Monte Carlo simulations
and generation of virtual population-specific physiological para-
meters
The urine-related BETDI values are intended to be applicable to a
diverse population, therefore it is more accurate if individual variability
is taken into account. This variability can be met in Httk with the
creation of a virtual population. Using the function “httkpop_generate”,
a virtual population with physiological data taken from the NHANES
(Johnson et al., 2014) may be generated. The sex, age range, weight
category, kidney function category, and ethnicity may be defined and
together they address the inter-individual variability. The character-
istics of a created virtual population may then be used to generate
population-specific parameters to run the PBK model.
We used the Yamane formula to define a sample size based on a
given population size (Yamane, 1967):
=
+
n N
N e[1 ( )]2 (1)
where n= sample size, N= population, e= error tolerance.
The Yamane formula was used to characterise European Union
general population size, based on a 508 million inhabitants, a sample
size of 400 is estimated. Samples of 400 and 4000 persons were feasible
in Httk, a Yamane-formula-based 400-subject and a 4000-subject po-
pulation were created to simulate the BETDI.
As done for the adult population, two populations, one with a larger
sample size than the other, were created for the children. The result is a
sample size of 1.000 made up of 500 males and 500 females and a
Table 1
Compounds selected for the HBM analysis and MRA, and their TDIs and RfDs, if available. For phthalates, in addition to the parent compound, information on the
main metabolite measured in urine as an indicator of exposure is presented. (Abbreviations: Abb.-Abbreviation, NA – not available; –/– - not applicable; Reference: 1.
EFSA, 2015; 2. U.S. EPA, 2019; 3. ITER, 2019; 4. Council of Europe, 2009; 5. Group TDI from EFSA OpenFoodTox, 2018; 6. Moos et al., 2017; 7. EFSA, 2005b; 8.
EFSA, 2005a.)
Parent Compound Abb. CAS TDIs/ADIs (mg/kg/day) RfD (mg/kg/day) Human urine metabolite measured Abb. CAS
Bisphenol A BPA 80-05-7 0.0041 0.052 –/– –/– –/–
Triclosan TCS 3380-34-5 0.0473 0.32 –/– –/– –/–
Benzophenone-3 BP-3 131-57-7 0.14 NA –/– –/– –/–
Methyl paraben MeP 99-76-3 105 NA –/– –/– –/–
Ethyl paraben EtP 120-47-8 NA –/– –/– –/–
n-Propyl paraben n-PrP 94-13-3 0.026 NA –/– –/– –/–
n-Butyl paraben n-BuP 94-26-8 0.026 NA –/– –/– –/–
Di-n-butyl phthalate DnBP 84-74-2 0.017 0.12 Mono-n-butyl phthalate MnBP 131-70-4
Butylbenzyl phthalate BBzP 85-68-7 0.58 0.22 Monobenzyl phthalate MBzP 2528-16-7
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sample size of 10.000 made up of 5.000 males and 5.000 females; all
between the ages of 6 and 11 years.
These populations constitute a random selection of individuals from
all weight categories (underweight, normal, overweight, and obese),
“non-hispanic white” and “other” ethnicities, with normal kidney
function and from 32 to 56 years of age for female adults and 6–11 for
children. For each individual in these populations and each chemical,
the function “get_httk_params” was used to generate parameters to run
the PBK model. When running this function, poor metabolisers were
considered.
2.4. Step 4: Forward dosimetry
As illustrated in Fig. 2, the forward dosimetry approach was used to
predict internal reference values (threshold concentrations in urine),
that can be used for screening level risk assessment, here called BETDI or
BERfD depending whether the basis for deriving them was a TDI or RfD
value, respectively.
In addition, forward dosimetry was carried out using estimated
daily intakes as input to predict corresponding urinary levels, which
could be compared to measured urine concentrations for evaluating the
quality of predictions of the two models.
2.4.1. Forward dosimetry using the ICF tool
The estimated daily intakes (EDIs) provided in the Norwegian HBM
project for the chosen individuals based on measured concentrations in
food, air, and dust, as well as the tolerable daily intakes (TDIs) and
reference doses (RfDs) of the chemicals were input into the model as
oral bolus doses (in mg/kg BW) at hour 0. No EDIs were measured for
triclosan.
The PBK model was run at 10,000 iterations per hour for 24 h. The
time to reach steady state was assessed using the equation Tss= 5*t(1/
2), with t(1/2) being the elimination half-life. Of all compounds under
consideration, triclosan takes the longest time to reach steady-state,
namely 145 h (6.04 days) if considering the maximum human elim-
ination half-life of 29 h (European Commission Scientific Committee on
Consumer Safety (SCCS), 2009). Therefore, to predict BE values at
steady state, all compounds were run for seven days to make sure that
all reached steady state at the end of simulation time. However, steady
state was only reached for BPA. As results for each BETDI, BERfD and
BEEDI and individual scenario (Woman/Child 1 and 2), the 24-h and
steady state Cmax values were recorded.
ICF predicts the concentration of the metabolites, which is directly
applicable for the phthalates, where relevant metabolites have been
analysed in the urine samples. For TCS and BPA, the ICF model predicts
the urinary concentrations of the glucuronidated metabolites (TCS-glu
and BPA-glu) while the hydrolysed TCS and BPA forms were analysed
in the urine samples. In order to match the results and compare pre-
dicted with measured concentrations, the resulting urine concentrations
of TCS-glu and BPA-glu were converted from µmol/L to ng/mL based on
the molecular weight of the parent compound. The parent compounds
are also predicted but result in concentrations that are very low, not
affecting the concentrations obtained via the conversion of glucur-
onidated forms.
2.4.2. Forward dosimetry using the Httk package
2.4.2.1. BETDI / BERfD calculations. To calculate urinary BETDI values
the TDI was input as a daily dose. Subsequently, “solve_pbtk” was run
for each individual in each population. When the model was run for the
time to reach steady state as defined by the function “calc_css”, it was
found that the amount excreted in the urine was still increasing at the
end of simulation time. Therefore, simulation times were defined as
shown in Table S5.1 to ensure that steady state is reached in the urine
by the end of the simulation.
The PBK output table generated for each individual includes the
amount of the chemicals in the renal tubules. This amount was
interpreted as amount excreted in the urine. The maximum amount
excreted per day was divided by the volume of urine expected to be
excreted (1600mL for adult females and 820mL for children (Sakhi
et al., 2018)) and expressed as ng/mL.
BETDI calculations were performed on two sets of 4000 and 400
women and two sets of 10,000 and 1000 children to evaluate whether
the BETDI values would differ considerably based on the different po-
pulations. The mean values differed very little between the larger po-
pulations versus the smaller ones but the standard errors of the mean of
the larger populations were smaller and therefore the 4000 and 10,000
individual sized populations were used. When choosing between the
two 10,000 and two 4000 individual populations the 5th percentile and
median BETDI values were compared. The differences were marginal
and the one population per age group with the overall lower BETDI
values was chosen.
Of the distribution of 4000 urine TDI equivalents excreted per day
in the adult female population and 10,000 values in the child popula-
tion, the 5th percentile, as a conservative measure, and the median
were used as BETDI values and compared with measured urine con-
centrations.
2.4.2.2. BEEDI calculations. For the evaluation of the model in Step 5,
the calculation of BE values based on estimated daily intakes (BEEDIs)
was used. The simulated BEEDIs were then compared to measured
urinary concentrations. In this study we used two types of EDIs as input
to the PBK models.
For the Norwegian Dataset, the EDIs were calculated based on
measurements of potential exposure sources found in the households,
such as concentrations in dust, air, and food (Sakhi et al. 2014). EDIs
were provided in the Norwegian dataset for phthalates and BPA for
40–46 mothers and children, depending on missing values for some
biomarkers. In line with the chemicals selected for this study, the only
EDI values from the Norwegian dataset were thus for BPA for the use in
Httk. For the calculation to be as accurate as possible and also allow for
the inter-individual differences the adult females were split into three
weight categories based on their body mass index (BMI): normal, obese,
and overweight. As reported by the WHO, adults are considered over-
weight if the BMI is equal or greater than 25, and obese if the BMI is
equal or greater than 30 (WHO, 2019). Twenty-eight (28) normal, 12
overweight, and 6 obese women with a mean weight of 62.2 kg,
75.2 kg, and 100.1 kg, respectively, were part of the Norwegian study.
Virtual populations were then created with the same number of
individuals as each category. As a result the three virtual populations
were: one of 28 normal weight individuals, one of 12 overweight, and
one of 6 obese.
The children of the Norwegian study population have a mean
weight of 34.3 kg. Their BMI values were presented. However, as their
individual ages and sex are unknown, they could not be classified into
the normal, overweight or obese categories. A virtual population of
children (both male and female) between 6 and 11 years old and of all
weight categories was created to see the ranges in weight and BMI. The
results showed that, in Httk, any child with a BMI over 25 is considered
obese, however, with BMIs under 25 the overlap between normal and
overweight was too close to compare without the information of age.
Therefore, looking at the HBM data of the children with EDIs and
corresponding urine measurements, only one child is obese and the
other 43 are normal/overweight. For the BEEDI calculation of the obese
child, an obese virtual population (200 boys and 200 girls) was simu-
lated and the individual with the closest BMI and weight (weight_adj in
Httk) to the child was chosen. For the other individuals, a virtual po-
pulation of 200 boys and 200 girls with the weight categories normal
and overweight was created. Individuals with weights or BMIs outside
the limits of those measured in the population were then eliminated. To
solve for the same number of individuals as in the data, 43 individuals
were randomly selected until the maximum, minimum, median, and
mean were similar to that of the HBM data.
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To calculate the BEEDI values for both adults and children, every
individual's EDI was used as a daily intake for the individual's corre-
sponding virtual population. Therefore, the same EDI has several BEEDI
values, one for each individual in the virtual population (e.g. 28 for the
adult female normal weight population). For each EDI the average of its
resulting BEEDI values was then compared against the corresponding
measured urine concentration.
To illustrate this with an example, e.g. a normal weight woman is
selected having an EDI of 1.40E-04mg/kg. This value is used as input
for the normal woman virtual population of 28 individuals (n=28),
thus generating 28 BEEDI values. The average BEEDI (∑BEEDI/28) was
0.131 ng/mL. The measured urine concentration of the individual
woman (with EDI= 1.40E-04mg/kg) was 1.88 ng/mL, thus an order of
magnitude higher than the simulated BEEDI of 0.131 ng/mL.
For the Danish study population, EDIs were not based on analytical
measurements in exposure sources. Instead, EDIs were calculated in a
reverse dosimetry approach in Frederiksen et al. (2013). We used 50th
and 95th percentile EDIs for BPA and TCS (Table S5.2) to derive BEEDI
values using the virtual population of Danish children created for the
calculation of the BETDI values (Fig. 4). Since the EDIs were derived
from aggregate data as the 50th and 95th percentile EDIs for boys and
girls between the ages of 6 and 10, separately, the virtual population
was filtered for 6 to 10 year olds and split into boys and girls (4081 and
4092, respectively). Then the maximum, minimum, and median of the
resulting BEEDI values were compared against the 50th and 95th per-
centile measured urine concentrations.
2.5. Step 5: Evaluation of modelling results
To test the model and estimate the quality and validity of the BETDI,
all predicted values – i.e. BEEDI, BETDI, BERfD – were contrasted with
comparable values. BEEDI, which represent the predicted urine con-
centration reached at oral exposure to the EDI, were compared to the
urine concentration measured in individuals. Under the assumption
that EDI values are reliable, the closer BEEDI are to measured urine
concentrations, the better the model is considered to perform. BETDI
and BERfD, which constitute safe on-going urine concentrations, were
compared to previously established BE values found in the literature or
public databases.
2.6. Step 6: Illustrative case study: single substance risk assessment
The BETDI and BERfD values derived using the ICF and Httk models
were compared to measured urinary levels. To interpret levels of in-
ternal exposure, the magnitude of exceedance of the established in-
ternal threshold and the percentage of the study population exceeding
these threshold values were calculated. The risk quotient (RQij), Eq. (2),
for each individual (i) is calculated for each chemical (j) by dividing the
concentration of the chemical (j) found in the urine of an individual (i)
by the BETDI values established in this report (see Table 3)
=RQ ij Urine concentration ij
BE j
( ) ( )
( )TDI (2)
2.7. Step 7: Illustrative case study: Mixture risk assessment
To illustrate a possible risk assessment based on the combined ex-
posure to multiple chemicals, a screening level mixture risk calculation
was performed. Parabens and phenols are both known as endocrine
disruptors, associated with effects on reproductive hormone and
thyroid levels (Aker et al., 2016). In order to assess the risk that in-
dividuals face from these chemicals as a whole a Hazard Index (HI)
approach was used. Ideally, only chemicals leading to the same adverse
outcome should be considered for the combined assessment and in
calculating the HI. However, including all chemical in a first screening
level estimate independent of the detailed MoA and adverse outcome
consideration is a worst-case conservative approach. If the resulting HI
is smaller than 1, it indicates that there is low concern. If a potential
concern is identified (i.e. if the HI > 1), a refinement looking more in
depth into grouping chemicals that are expected to contribute to a
specific effect should be performed, but this is out of scope of this case
study.
The HI, Eq. (3), is calculated by summing all of the risk quotients
(RQ), Eq. (2), of an individual, each RQ is the concentration of a che-
mical (j) found in the urine of an individual (i) divided by the BETDI
values established in this report (see Table 3).
∑=HI ij RQ ij( ) ( ) (3)
3. Results
3.1. Deriving BEEDI and BETDI values with IndusChemFate and comparison
to measured concentrations of four individuals
3.1.1. Calculations for Norwegian women and children
Using the calculated EDI from external sources of the Norwegian
data set, the corresponding urinary concentrations BEEDI were simu-
lated with ICF and compared to the measured urinary concentrations in
the Norwegian HBM dataset. Two female adults and two children were
randomly selected from the normal and obese groups, to test the ICF
model. For data protection reasons, individual urine concentrations and
EDI values are not presented, but the factor of deviation between
measured and predicted values are shown (Tables S5.3–S5.5).
The results from the 24 h simulation show that overall measured
urine concentrations and estimated EDI-based urine concentrations
differ by three to five orders of magnitude (Tables S5.3 and S5.4).
However, the Cmax urine concentration predicted for BPA only differs
by approximately one order of magnitude from the measured urine
concentration. For DnBP and BBzB, estimated EDI-based urine con-
centrations (BEEDI) are always lower than measured urine concentra-
tions. This could indicate that there are other external sources of these
chemicals that were not covered in calculating the EDI, but it can also
indicate that ICF is underpredicting. The BEEDI of BPA for the normal
weight adult female and the obese child are higher than measured
concentrations in urine. Unfortunately, there are no measurements to
estimate EDIs for triclosan so no BEEDI was calculated for this com-
pound.
When running all compounds for the period of seven days, only BPA
reaches a steady-state concentration. The venous blood concentration
of all other substances continues to steadily increase, even when the
simulation is run for a period substantially longer than seven days
Fig. 4. Calculation of EDI values from urinary concentrations in a reverse do-
simetry approach and using these as input doses in a forward dosimetry ap-
proach to obtain BEEDI values to evaluate model performance.
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(100–300 days). Therefore, steady state simulations are only presented
for BPA (Table S5).
Interestingly the steady state BETDI, BERfD and estimated BEEDI va-
lues are very similar to the 24-h Cmax concentrations for BPA. All
measured urine concentrations are below the calculated BETDI and
BERfD values. Also, measured urine concentrations and those estimated
from the EDI differ by approximately one order of magnitude, which
can be considered a reasonable result.
It is difficult to assess the uncertainty underlying these results. In
conclusion, predictions for BPA are more accurate than predictions for
other substances in ICF since steady state was reached only for BPA.
This may be related to the fact that the BPA was a test chemical for the
development of the ICF model and its data are already provided in ICF
when the model is downloaded from the Cefic-LRI website.
3.1.2. Calculations for Danish children in IndusChemFate
As ICF only reaches steady state for BPA, this was the only chemical
used. To evaluate the ICF model, the EDI values calculated in
Frederiksen et al (2013), were input to ICF to recalculate the urinary
concentration. The 50th and 95th percentile EDIs were used. To further
evaluate the ICF model, the average weights of the boys and girls were
calculated and input as both a scenario of normal weight child and
obese child to visualise the difference in the model output. The two
scenarios differ only by the fractions used to calculate the tissue vo-
lumes.
The results of this comparison show that ICF overestimates the
concentration of BPA found in the urine based on the EDIs by a factor of
4–8. The normal child parameters are a closer fit for the bodyweights
introduced and the predictions are closer for the 50th percentile EDIs
(Table 2).
3.2. Derivation of BEEDI and BETDI values with Httk and comparison to
measured concentrations
3.2.1. Derivation of BEEDI values for BPA in Httk
In order to test the model and estimate the validity of forward do-
simetry results in view of deriving BETDIs, EDI values for BPA derived
from ambient air, dust, and food concentrations for the Norwegian data
set were used to calculate urine-based BEEDI values which are
subsequently compared to measured urine concentrations. Due to
availability of EDI based on external exposure sources, this was only
possible for BPA. Fig. 5A and B show the calculated BEEDIs for Nor-
wegian women and children, respectively, compared to the range of
measured urine concentrations, presented as 5th and 95th percentiles.
The deviation between measured and simulated urinary concentrations
is on average two to three orders of magnitude, with a minimum of one
and maximum of five orders of magnitude. The higher the EDI input
values used as daily doses, the closer the predicted results become to
the measured urinary concentrations. This may indicate that either the
higher the EDI, the more complete and reliable this value is, which
results in a more reliable BEEDI, or that Httk performs better with higher
oral doses.
For the Danish data set, the BEEDIs were calculated using the EDIs
estimated from reverse dosimetry, focusing on the 50th and 95th per-
centile EDIs. As shown in Table 2, for all cases (BPA and TCS, boys and
girls, 50th and 95th percentile), the Httk model results underestimate
the urinary concentrations. The predictions which are closest to the
measured urinary concentrations are the maximum values which are
underestimating by a factor of 2.5–3.8 for BPA and a factor of 3–43 for
TCS. In all cases the results for the 95th percentile were better predicted
than for the 50th percentile, as also seen for the Norwegian data set that
Httk performed better at higher concentrations.
3.2.2. Httk results for BETDI calculations
TDI values for the eight selected chemicals were used as input in
Httk in order to calculate internal threshold BETDIs. Virtual populations
were run, consisting of 4000 female adults and 10 000 children which
ingested daily doses of the TDI until steady state is reached in the urine.
Table 3 shows the predicted BETDI values based on the 5th percentile
and the median of the distribution of maximum urinary concentrations
of virtual populations.
The 5th percentile BETDI values are all at least half the concentration
of the median BETDI values. For MeP and EtP only a group TDI is es-
tablished, therefore the BETDI is a result of the sum of MeP+EtP. The
values for this sum were obtained by grouping all the urine TDI
equivalents together and calculating the 5th percentile and median.
Table 2
Urinary concentration estimates of BPA and TCS. 50th and 95th EDI values obtained by reverse dosimetry from urinary concentrations, were used as daily doses in
forward dosimetry in order to evaluate the generic models. The ICF results were obtained for BPA only, as TCS did not reach steady state in the model. The ICF
scenarios for normal and obese child were used, however using the same input weight, i.e. a body weight of 35.2 kg for the boy and 31.6 kg for the girl, respectively.
For the Httk model, virtual populations as described in Section 2.4.2.2 were used for the simulation of BPA and TCS. Using the 50th and 95th percentile EDI as input
to the model, the resulting minimum (min), maximum (max), and median urinary concentrations for the virtual populations are shown.
Boys
EDI HTTK simulated results (ng/mL) ICF simulated results, normal child
(ng/mL)
ICF simulated results, obese child
(ng/mL)
Measured urine (ng/
mL)
Percentile mg/kg/
day
min max median
BPA 50th 8.0E-05 0.01 0.88 0.04 13.00 14.82 3.33
95th 3.1E-04 0.02 3.12 0.15 51.05 58.21 7.75
TCS 50th 2.8E-05 0.0002 0.03 0.001 – – 1.45
95th 1.4E-02 0.09 16.76 0.48 – – 186.18
Girls
EDI HTTK simulated results (ng/mL) ICF simulated results, normal child
(ng/mL)
ICF simulated results, obese child
(ng/mL)
Measured urine (ng/
mL)
Percentile mg/kg/
day
min max median
BPA 50th 4.97E-05 0.00 0.65 0.02 8.11 9.24 2.20
95th 3.16E-04 0.02 4.16 0.15 51.54 58.77 11.20
TCS 50th 1.88E-05 0.0001 0.02 0.001 – – 0.80
95th 1.23E-02 0.06 12.63 0.41 – – 37.01
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3.3. Comparison of derived BETDI values with previously established values
In order to better understand whether the BETDI values calculated in
ICF and Httk are similar to previously established BE values of the
compounds considered here, a search of comparable values was per-
formed. Only TCS and BPA urine-based BE values were found in the
literature. These had been established by the German HBM Commission
using the term “HBM-I” values (Angerer et al., 2011) on the basis of TDI
values published by Krishnan et al. (2010a, 2010b). These BE values are
for TCS 3000 and 2000 ng/mL for adults and children, respectively, as
well as for BPA 200 and 100 ng/mL.
Table 4 shows that for TCS, all BETDI values obtained from Httk and
ICF differ from previously established levels by around four orders of
magnitude. It needs to be taken into account, however, that for TCS the
TDI value used for establishing the HBM-I-values was higher than the
TDI used in our study. For BPA, however, existing BE values are in the
same order of magnitude when considering Cmax-based BETDI values
calculated in ICF, for female adults deviating only around a factor of 2.
The ICF-related values shown here are only based on two individual
scenarios offered by the model. Therefore, a range of BETDI values re-
flecting inter-individual variability is not obtained with this model.
The BETDI values for TCS are much lower than the established HBM-
I-values, thus being more conservative, which is also the case for Httk
derived values for BPA. Only for ICF derived BETDI values are higher
and therefore less conservative, even if they are closest to the pre-
viously established values.
3.4. Evaluation of ICF and Httk results: uncertainties and assumptions
Overall, it is difficult to evaluate the validity of the ICF and Httk
results as the only exercise undertaken to test the model was the
Fig. 5. A. BEEDI concentrations for BPA based on EDIs of 28 normal weight, 12 overweight and 6 obese female adults of the Norwegian group of women in relation to
the 5th and 95th percentile of the measured urine concentration of this study population. B. BEEDI concentrations for BPA based on EDIs of 43 Norwegian children in
relation to the 5th and 95th percentile of the measured urine concentration of this study population.
Table 3
BETDI values established in Httk in virtual populations of 4000 female adults
and 10,000 children based on daily doses of the TDI.
BETDI values (ng/mL)
Female adults,
5th percentile
Female
adults,
median
Children, 5th
percentile
Children,
median
MeP 1008.77 2971.53 716.06 1944.75
EtP 1886.90 5393.45 1361.21 3670.23
MeP+EtP 1217.50 4047.33 864.80 2693.16
PrP 4.73 13.92 3.41 9.45
BuP 4.56 12.86 3.19 8.65
TCS 0.89 2.57 0.64 1.73
BP-3 11.09 32.05 8.05 21.62
BPA 1.08 3.08 0.79 2.09
J. Pletz, et al. Environment International 143 (2020) 105978
9
forward dosimetry approach using EDI values of both Norwegian po-
pulations. This exercise showed that simulated urine level BEEDI values
differ by on average two to three orders of magnitude from measured
urine concentrations in 46 adult females and 43 children. These partly
exceed the generally accepted difference of one order of magnitude
between predicted and measured results. These results show that fur-
ther improvements could be achieved by introducing refined parameter
values (calibration) of the PBK model platforms, this was however be-
yond the study design.
It is crucial to consider that, besides uncertainties inherent in the
ICF and Httk predictions, several uncertainties are likely to be
associated with the EDI values used. Typically, these uncertainties re-
late to source variability (e.g. changes in emission rates), variability of
model input parameters to calculate the EDI, and metabolic variability
within a population and with respect to changes in metabolic rate of an
individual which are not considered when calculating the intake (Hines
et al., 2011). The approach used to calculate EDI values for Norwegian
adult females includes assumptions of the amount of drinking water
consumed and indoor air inhaled as well as three scenarios for dust
ingestion in order to achieve sufficiently certain results (see Haug et al.,
2011). Another aspect contributing to uncertainty of BEEDI results is
related to the use of the EDI value as a whole as oral dose even though a
Table 4
BETDI values calculated in ICF and Httk for female adults and children compared to previously proposed BE values (HBM-I-Werte) by the German HBM Commission.
TCS BPA
Cmax-based BETDI values established in ICF Normal weight female adult (ng/mL) 0.44a 427.92b
Obese female adult (ng/mL) 0.39 a 437.09b
Normal weight child (ng/mL) 0.73 a 649.20b
Obese child (ng/mL) 0.67 a 739.19b
BETDI values established in Httk Female adults, 5th percentile (ng/mL) 0.89 1.08
Female adults, median (ng/mL) 2.57 3.08
Children, 5th percentile (ng/mL) 0.64 0.79
Children, median (ng/mL) 1.73 2.09
Existing BE values (HBM-I-values) Adults (ng/mL) 3000c 2500d 200e
Children (ng/mL) 2000c 1500d 100e
a BETDI values for TCS were derived in ICF using 24 h simulations, since a steady state was not reached.
b BETDI values for BPA were derived in ICF using steady state simulations, which is the best comparable to the concept of deriving TDIs as a safe dose based on
chronic daily exposure. The difference between 24 h simulations and steady state simulations for BPA in ICF are however small (see Table S5.3–S5.5).
c HBM-I-values for TCS are based on a TDI of 0.12mg/kg BW and day as opposed to 0.047mg/kg BW and day which was used for BETDI values established in this
study
d HBM-I-values for BPA based on a TDI of 50 µg/kg BW and day by EFSA (German HBM Commission 2012; Apel et al., 2017)
e HBM-I-values for BPA based on a TDI of 4 µg/kg BW and day by EFSA [2015] (update by German HBM Commission 2015; Apel et al., 2017)
Table 5
Assumptions, limitations and uncertainties of the ICF and Httk tools.
IndusChemFate (ICF) High-Throughput Toxicokinetics (Httk)
Problem formulation How can PBK models be used to interpret HBM data in the context of assessing the risk of environmental pollutants?
Assumptions Vmax and Km were searched in the literature and scaled up to same unit to
input into the model.
Absorption rate calculated using a QSAR model.
Predictions of input parameters based on QSAR.
Intake is assumed to come from the oral route, although it is known that it
can also come from air, dust or food. Urinary excretion is driven by the
lipophilicity.
The QSPR calculating solubility assumes that human blood consists to
0.7% of lipids.
8% of arterial blood is turned into primary urine.
No tubular resorption of very soluble substances with a
log(Kow) < −1.5.
Physiological parameters do not change by sex or over time.
A simple PBK Model will represent the complexity of the human body.
All Httk input parameters are correct, except the BW and the p value related
to the intrinsic clearance of TCS which were changed (p= 0.06).
Intake is assumed to come from the oral route, although it is known that it can
also come from air, dust or food.
Perfusion-limited kinetics.
Rblood2plasma is constant throughout the body.
Clearance is assumed to be relative to the amount unbound in whole blood
instead of plasma, but converted to use with plasma concentration.
Negligible blood volume fractions in all tissues to justify dividing by the tissue
volume without a blood volume fraction and partition coefficient dependency
in PBK tissue concentration equations.
Wetmore data assumed fub= 0.005 for chemicals with fub below the limit of
detection.
Linear, non-saturated metabolism.
Input parameters Sourced from different databases and the public literature which used a
wide variety of techniques;
Uncertainty in in vitro data (e.g. nominal as opposed to effective
concentration is recorded);
In vitro to in vivo extrapolation uncertainty (e.g. uncertainty related to the
scaling factor used for Vmax values);
Only metabolism in liver was considered;
Lack of detailed consideration of specific protein binding, interaction with
intestinal flora, intestinal transport, and excretion by faeces.
Prediction for individuals only; body weight can be amended;
Lack of certain input parameter values (e.g. Vmax and Km).
Fewer variety of sources and higher consistency of methodology;
Uncertainty in in vitro data (e.g. nominal as opposed to effective
concentration is recorded);
In vitro to in vivo extrapolation uncertainty;
High degree of QSAR-generated parameters;
Allows only for metabolism in liver;
Prediction for populations which are based on U.S. NHANES data; degree of
variability to European/Scandinavian population unclear.
Model structure High number of compartments;
Steady state not reached for most compounds;
Mass balance can easily be checked but shows errors, especially in
children's populations;
Moderate number of compartments;
Simulation of metabolite kinetics unavailable;
Conversion from chemical amount in renal tubule to urine concentration
necessary;
Model output Uncertainties underlying EDIs and TDIs;
Uncertainties in urine concentration measurements, in particular related
to the use of a one spot measurement of non-persistent compounds.
Uncertainties underlying EDIs and TDIs;
Uncertainties in urine concentration measurements;
Size of adult female population above 4.000 individuals gave error message.
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fraction of it is related to inhalation exposure. Furthermore, if other
exposure sources, not captured via the monitoring of food, dust etc. are
contributing substantially to the overall exposure, the internal exposure
will of course also be underestimated (National Research Council, 2009;
Bang et al., 2012; Yao et al., 2018). Relevant dermal uptake has been
shown for semi-volatile chemicals, e.g. for phthalates from clothes
(Morrison, Weschler and Bekö, 2017).
Interesting to note is that Httk predicted BEEDI concentrations (in
ng/mL) follow the same trend as EDIs (mg/kg BW) which indicates
linearity between model input and output reflecting linear biological
processes. However, metabolism may for instance saturate and there-
fore be non-linear.
ICF predictions for BPA are considered more accurate than predic-
tions for other substances in ICF. The reason for this is primarily that
steady state was only reached for BPA. Because of this, ICF results are
not considered for single substance risk assessment (Step 5) and mixture
risk assessment.
When compared to previously established TDI-based BE con-
centrations in urine, the BETDI values obtained with Httk appear to be
conservative. Additionally, reference values such as TDIs and RfDs also
bear uncertainties (e.g. extrapolation from animal to human popula-
tions, see also Hays et al., 2007) and are continuously updated which
indicates to some degree lack of robustness overall.
A summary of the limitations and uncertainties of the model is given
in Table 5. A full evaluation of the two PBK modelling platforms is
available in the supplementary material S4.
An OAT sensitivity analysis was performed for BPA using
IndusChemFate showing that if there is a 10% increase/decrease of the
value (Vmax and Km) this will influence the model output in urinary
excretion. Also organ and body weight were changed by 10% but this
did not influence the model output.
An OAT sensitivity analysis was performed for BPA using Httk
showing that if there is a 10% increase/decrease of the value (CLint)
this will influence the model output in urinary excretion.
3.5. Case study: applying derived BETDI values for single substance risk
assessment
To interpret the measured urinary concentrations, they can be
compared to toxicological and health based reference values. BETDI
values can serve as such reference values to compare to. This study
looked into possible generic methodologies and related limitations to
derive such BETDI values. The application of the BETDI values derived
here is performed for illustration of the possible use and cannot be
considered as detailed risk assessment. Results need to be interpreted
with care and uncertainties around the BETDI values need to be taken
into account as discussed in Section 3.4.
The results based on the BETDI and BERfD values established using
ICF are shown in Tables S5.3–S5.5. When considering the calculated
BERfD and BETDI values in comparison to the measured urinary con-
centrations for the four chemicals, all four individuals appear to be
exposed to concentrations below the BPA and Triclosan internal RfD or
TDI values. For BBzP, urine concentrations measured in all four in-
dividuals are below the BETDI but for Woman 1 and Child 2 their
measured urinary concentration is higher than that of the BERfD. For
DnBP, all measured urine concentrations are above the calculated BE
values for all four individuals by one to two orders of magnitude.
Urinary concentrations above BERfD or BETDI are indicating a potential
risk.
Then, measured urinary concentrations were compared to the Httk
simulated BETDI values, both 5th percentile and median (Fig. 6).
Comparing the results for the different chemicals assessed, exposure to
BPA seems to be of greatest concern with most exceedances of the de-
rived threshold BETDIs. Over all chemicals and populations, and con-
sidering both the 5th percentile and median based measures, 50% and
over exceed the BETDI established for BPA. With respect to the 5th
percentile based BETDI, 95%, 100% and over 70% of Norwegian adult
females, their children, and Danish children, respectively, exceed this
level. While TCS exposure only exceeds both BETDI values in 10–21% of
the Norwegian adult and child populations, 63 and 30% of the Danish
children exceed the 5th percentile and median based measures, re-
spectively. In both groups of children, both PrP BETDI values are ex-
ceeded by 9 to 26% of individuals while 34 and 48% of adult females
show higher urine concentrations. Considering the 5th percentile based
BETDI for BP-3, approximately 35 to 40 of both Norwegian populations
Fig. 6. A. Number of individuals (in %) in the Norwegian adult females' group
whose urine concentration exceed the 5th percentile and median based BETDI
values. B. Number of individuals (in %) in the Norwegian children group whose
urine concentration exceed the 5th percentile and median based BETDI values.
C. Number of individuals (in %) in the Danish children group whose urine
concentration exceed the 5th percentile and median based BETDI values.
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show higher levels of exposure, whereas less than 20% (including the
Danish group) exceed the median-based value. Exposures to MeP+EtP
and BuP appear to constitute the least concern. Up to 6% of all popu-
lation groups exceed both 5th percentile and median based BETDIs for
these chemicals.
As expected, the 5th percentile based BETDI may be a rather con-
servative measure. In the cases of BP-3 in Norwegian children and fe-
male adults, BPA in adult females, and n-PrP and TCS in Danish chil-
dren, the difference in the number of individuals exceeding the 5th
percentile and the median based BETDIs is substantial. In cases where
the BETDI is exceeded by roughly 20% or less of the population, the
difference to the median-based BETDI does not seem to be significant.
3.6. Case study: Applying derived BETDI values for mixture risk assessment
As described above, the aim of this study was to investigate the
suitability and limitations of using generic PBK models to derive BETDI
values for a larger number of chemicals in a similar way. The idea is to
facilitate the use of HBM data in risk assessment for a wider range of
chemicals and in particular in the context of assessing mixtures. The
application of the BETDI values derived here is performed for illustration
of the possible use and cannot be considered as detailed risk assess-
ment. Results need to be interpreted with care and uncertainties around
the BETDI values need to be taken into account as discussed in Section
3.4.
In a screening level approach, the Hazard Index (HI) was calculated
summing up the risk quotients for all chemicals independent of the
specific endpoints of the chemicals. If the resulting HI > 1 it indicates
a potential risk and the need for further refined assessments. The HI was
calculated for each individual against the two BETDI values established
using virtual populations in Httk, i.e. 5th percentile BETDI and median
BETDI. In addition, a HI was determined for each study population in
order to represent the risk each one faces. These HIs were calculated
using the median measured urine concentration of each chemical
against the median BETDI calculated. It should be noted that the median
is estimated for some chemicals with fewer samples than for others (i.e.
n-BuP).
The HI for all three study population groups (Norwegian female
adults, Norwegian children and Danish children) is above the re-
commended maximum of 1 and is driven mainly by the phenols group
(Fig. 7). More information is presented in the supplementary material
(Figs. S5.1 and S5.2) investigating the impact of selecting different
percentiles. In fact, the phenols make up over 95% of the HI for both
children populations. In terms of chemicals, BPA has the highest HQ in
all of the populations, whilst n-BuP and MeP+EtP have the lowest. In
addition, two chemicals of note for the Norwegian mothers are BP-3
and n-PrP. This last one shows that the mothers are more exposed to
parabens than their children, however, their HI is lower than both
children populations. Finally, although Norwegian children have the
highest HI they appear to be less exposed to TCS than the Danish
children. In the comparison between the Norwegian and the Danish
children, it needs to be taken into account however, that samples were
taken in different years (2012 for Norwegian study and 2006/2007 for
the Danish study), so that a decrease of external exposure concentra-
tions over time might also play a role.
4. Discussion
The aim of this study was to investigate and illustrate the suitability
of generic PBK models to derive biomonitoring equivalents of health
based guidance values, such as BETDI values. The need for such values to
facilitate the interpretation of HBM data has been acknowledged,
however considering their limitations and using them as a screening
tool (Louro et al., 2019; HBM4EU Deliverable D 5.4). Deriving internal
reference values is a difficult task. When performed, all related un-
certainties must be taken into consideration. Such values are
established for example by the German HBM Commission for 19 sub-
stances using various data types and approaches. Furthermore, the EU
project HBM4EU has started to derive HBM health based guidance
values for their priority substances, also using PBK modelling. This
study focussed on the applicability of generic PBK models, as these may
assist in deriving such values for a wider range of chemicals that are
measured in humans and are continuously growing in number.
ICF and r/Httk were used in this exercise, which are probably just
one example of the mathematical models that could be used to interpret
HBM data. However, to improve the overall HBM interpretation other
examples of exposure platform like INTEGRA, MERLIN EXPO, and HBM
Simulator could be investigated. These platforms are important tools for
analysis of indirect exposure assessments allowing for estimation of
individual or population exposure patterns.
Fig. 7. Comparison of median measured urine concentrations to threshold
concentrations “median BETDI” established in this study using Httk. Risk
Quotients for individual chemicals (grey bars), sum of risk quotients for che-
mical groups phenols and parabens (green bars), and the overall Hazard Index
(HI, red bars) are presented for (A) Norwegian female adults, (B) Norwegian
children, (C) Danish children. The risk quotients and HI using the BETDI values
established in this study have to be interpreted with care, taking into account
the uncertainties around the BETDI values and the orders of magnitude differ-
ence in them when using different models or comparing to formerly established
BE thresholds. (For interpretation of the references to colour in this figure le-
gend, the reader is referred to the web version of this article.)
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4.1. Suitability of the two generic models ICF and Httk
Both, ICF and Httk, were selected among the publicly available PBK
model tools that could be easily used for a wider range of chemicals.
The case studies explored the suitability of applying a generic approach
to deriving urinary reference values to facilitate the interpretation of
HBM data in a chemical risk assessment context for single substances
and mixtures.
ICF contains 11 body compartments and by default assumes phy-
siological and anatomical parameters of a 70 kg reference human.
However, several subjects can be selected, such as man, woman, and
child, with normal weight or obese. The model contains algorithms as
Quantitative Structure-Property Relationships (QSPRs) for blood:air,
tissue:blood partitioning and for urinary excretion; estimating con-
centrations and amounts in body fluids (air excreted, urine and blood)
and in organs after inhalation, oral intake or dermal exposure according
to user defined exposure scenarios. For the present work, various po-
pulation scenarios were selected, e.g. normal child in rest or obese
woman doing light work. As organ and tissue volumes and blood flows
are scaled relative to the body weight, these are amended for a pre-
diction for a normal or obese woman or child. Besides calculating
parent and metabolite concentrations in organs over time, the amount
excreted in urine is also predicted. ICF was primarily selected because
of its user-friendly qualities. Furthermore, conversion of a parent
compound to one or more metabolites may be modelled in parallel. This
is particularly relevant for phthalates as they are rapidly metabolised
(Frederiksen, Skakkebæk and Andersson, 2007) and the concentration
of some of their metabolites are an adequate indicator of exposure to
the parent compound (Ramesh Kumar and Sivaperumal, 2016). A
steady-state concentration was only reached for BPA whereas the ve-
nous blood concentration of all other substances continues to steadily
increase, even when the simulation is performed for a period of
100–300 days.
Httk constitutes a compilation of a one, three, and seven-compart-
ment PBK model intended to compute concentration vs. time curves.
Here, the model was used for all urinary predictions, and the number of
days to reach steady state was calculated for all compounds modelled.
Models are parameterised with high-throughput in vitro data and
structure-derived physicochemical properties of over 1300 compounds
and physiological data from the most recent U.S. Centers for Disease
Control and Prevention (CDC) National Health and Nutrition
Examination Survey (NHANES) data. At present, there is no option to
estimate metabolite concentrations in the current version of the Httk
which is why the model could not be used for phthalates. The exposure
route applied was oral - via ingestion and the seven compartmental
model was used to run the simulations. Httk was primarily selected
because of the richness of data made available within the model. Httk
contains parameter data for n-propyl and n-butyl parabens but not their
isomers. For certain individuals of the Danish dataset only measure-
ments of the sum of n- and i-propyl as well as n- and i-butyl parabens
are available. In these cases, data points based on sum measurements
are plotted separately in the graph (see Fig. 7C).
One advantage of Httk is that the population variability can be
considered by using virtual populations. Many different approaches
exist to determine a sample size. For simulations considering the gen-
eral population, Monte Carlo simulations with a sample size of 10,000
is often used (Slob, 2006; Sprandel et al., 2006; Goutelle et al., 2009;
Punt et al., 2016). However, a study on the number of replications re-
quired in Monte Carlo simulations found that for all 22 studies con-
sidered, the minimum recommended number of replications (which
corresponds to the sample size) is less than 10,000 (Mundform et al.,
2011). Overall, 7500 to 8000 replications produce robust results, while
in a number of cases 5000 may be enough (Mundform et al., 2011).
Others use the Yamane formula to define a sample size based on a given
population size (Yamane, 1967). In the present work we used the Ya-
mane formula for the population of the European Union sized 508
million inhabitants, with estimation of a sample size of 400 people.
Unfortunately, in Httk, a virtual population of 10,000 females could not
be created and most attempts to create a population of 5000 females
produced error messages. As samples of 400 and 4000 are feasible in
Httk, a Yamane-formula-based 400-subject and a 4000-subject popu-
lation were created to simulate the BETDI which were compared to urine
concentrations measured in mothers. For the population of children, to
be similar to the two mother samples, 500 males and 500 females of the
same age group were produced. These populations constitute a random
selection of individuals from all weight categories (underweight,
normal, overweight and obese), “non-hispanic white” and “other”
ethnicities, with normal kidney function and from 32 to 56 years of age
for female adults and 6–11 for children. When the model was run for
the time to reach steady state as calculated by “calc_css”, it was found
that the amount excreted in the urine was still increasing at the end of
simulation time. Therefore, simulation times were defined to ensure
that steady state is reached in the urine by the end of the simulation.
The performance of the PBK models for the chemicals under in-
vestigation was evaluated in two ways: (1) for the Norwegian dataset,
estimated daily intakes resulting from external exposure measurements
in dust, air, and food were used to simulate related urinary con-
centrations, which were subsequently compared to measured urinary
concentrations. (2) for the Danish dataset, a reverse dosimetry ap-
proach was used to calculate EDIs based on urinary concentrations.
These EDIs were then used in the models to predict urinary con-
centrations and to compare to the measured urinary concentrations
again. Higher predicted BEEDI values can be considered more con-
servative. Predicted concentrations were mostly orders of magnitude
lower than the measured urinary concentrations. This underprediction
indicates that the BETDI values established in the same way tend to be
too low, i.e. too conservative, indicating a risk at very low levels. This
was also confirmed when comparing to formerly established HBM-I
values by the German HBM Commission, which were much higher for
TCS and BPA than the BETDIs of this study.
The predictions of a generic PBK model may be more reliable if BE
values are derived for a specific population by adapting the model’s
physiological parameters, e.g. intrinsic clearance and kidney function,
to said population. Another option for the future is to use chemical
specific PBK models to establish general BE values for children and
adults using more general assumptions about a wider (e.g. European)
population to be used as a virtual population.
To further assess the suitability of the models, more compounds
should be studied and the influence of selected parameters further in-
vestigated. The use of virtual populations and considering different
percentiles offers one way of differentiating and taking into account of
population variability. To further facilitate evaluation of model pre-
dictions, more data on external exposure would be of value in order to
estimate more reliable EDI values.
The appropriateness and predictive ability of the two PBK models
were further examined. We applied the WHO (2010) and OECD
(Sachana et al., 2019) criteria to assess model credibility, although in
the present study we use PBK model platforms and not compound-
specific PBK models. As the WHO (2010) reports, there are potentially
two types of uncertainties and built-in errors in the models and in the
platforms:
Firstly, the structural uncertainty of the model was assessed
(Supplementary Material S4). To this end, the PBK model platform
equations and mass balance were checked. To our knowledge the bio-
logical basis was respected as was the mass balance (total absorbed
mass was equal to the intake dose given). However, the total absorbed
mass of the parent compound should also be equal to the sum of mass of
parent+metabolites in all model compartments plus the mass excreted
in urine and/or exhaled air (total sum). In the ICF model there is a 3%
discrepancy which means the model underpredicts the “total sum”.
Secondly, the parameter uncertainty was evaluated. For ICF pre-
dictions, this information was searched in the literature and scaled
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according to an accepted IVIVE approach. It is unclear why steady-state
concentrations were not reached for the majority of compounds tested.
However, it may be worth searching for additional data (or deriving
these via read-across) to increase knowledge of parameter ranges sui-
table for the populations of women and children.
In Httk, the steady state concentration (Css) predicted for most
chemicals analysed by Wambaugh et al. (2018) was overestimated by
more than an order of magnitude. Accordingly, the total clearance
(CLtot) was underestimated, more for non-pharmaceuticals, which
implies that urinary concentrations are likely to be underestimated.
CLtot is derived from the sum of hepatic metabolism and passive glo-
merular filtration in the kidney (Pearce et al., 2017). Hepatic metabo-
lism is calculated with a well-stirred model using scaled in vitro intrinsic
hepatic clearance data and for both hepatic metabolism and glomerular
filtration the fraction unbound is considered. Therefore, the chemical-
specific parameters driving CLtot are hepatic clearance and the fraction
unbound. For BPA, Wambaugh et al. (2018) showed that the in vivo
estimated CLtot is approximately two orders of magnitude higher than
the in vitro predicted CLtot. An underestimation of CLtot may be in-
terpreted as either an underestimation of hepatic clearance, glomerular
filtration in the kidneys or both. Metabolism of BPA is occurring ra-
pidly, predominantly in the liver and via glucuronidation, and to a
lesser extent via sulfation (Völkel et al., 2002; Kurebayashi et al., 2010).
As mentioned earlier, measured BPA urine concentrations include hy-
drolysed BPA glucuronide (and sulfate) concentrations which are not
included in Httk predicted urine concentrations of BPA. Besides the
possibility that hepatic clearance and the fraction unbound of BPA may
be underestimated which would explain the overestimation of Css, a
major factor contributing to the difference between in vitro and in vivo
CLtot is likely also related to a fast renal excretion of BPA glucuronide
in vivo due to a high fraction unbound (estimated at 0.95 by Edginton
and Ritter, 2009). No data was found in the literature and the Me-
trabase database (http://www-metrabase.ch.cam.ac.uk) indicating that
BPA is excreted via processes other than glomerular filtration, such as
active transport. Due to the underestimation of CLtot for BPA by two
orders of magnitude, the results indicating that individuals’ exposed to
BPA exceed the safe level need to be revisited, meaning that a more
refined approach is needed to generate the BETDI for BPA.
Similar to BPA, TCS is found to be predominantly excreted as glu-
curonide in the urine of humans while concentrations of the parent and
TCS sulfate are negligible (Arbuckle et al., 2015). As the calculated
BETDI for TCS is related to the concentration of the parent only, com-
paring this value to the measured urine concentration, which is pre-
dominantly based on excreted TCS glucuronides, is suboptimal. A pre-
dicted BETDI accounting for both, TCS and TCS-glu, would be
considerably higher.
However, since the aim of this study was to evaluate the perfor-
mance of Httk without making vast amendments to inherent parameter
values, the results were generated as presented above.
Additional assumptions and uncertainties for model and parameter
uncertainties are reported in Table 5.
Finally comparing a model prediction with the HBM experimental
data is a validation step that establishes confidence in the model. In the
case of BPA using ICF the simulated urinary concentration was over-
estimated by a factor of 4 and 8, slightly higher than the two fold cri-
terion of model acceptability by WHO (2010) but within the one order
of magnitude, so still reasonable. To correct for this discrepancy in
model overprediction the model could be refined or calibrated in order
to better fit the values. However, we did not wish to refine the model
structure or the input parameters, but rather to assess the “readiness” of
such model platform as such. This is because the aim of the study was to
investigate whether, based on the example of two generic PBK models,
it would be feasible to derive BETDI values that could be used in
screening level assessments of HBM data in a short time for a larger
number of chemicals with different characteristics.
4.2. Limitations and strengths of comparing modelling results with urinary
concentrations
One of the major limitations in working with short half-life bio-
markers is the within individual variability. However, as described in
Section 2.1, in the Norwegian study, the calculated 24-h intraclass
correlation coefficients (ICCs) were moderate to high for most of the
phthalates and phenols indicating that the within individual variation is
less than the between individual variation during 24-h (Tables S1.1 and
S1.2). Thus, we could use 24 h or steady state urine concentrations as
modeling outputs for BETDI or BERfD and compare them with the HBM
study. The 24-h ICCs of the studied phthalates (DnBP and BBzP) and
phenols (BPA and TCS) are high. These moderate to high ICCs indicate
that one spot urine sample can be used to estimate the exposure to
phthalates and phenols.
Another important consideration in interpreting the data is the
timing between exposure episode and urinary void. If exposure does not
result in a steady state – which is often the case for many non-persistent
chemicals as BPA - the concentration measured in spot (or morning)
void will depend on the timespan since exposure occurred and the ur-
inary void. While 24-h urine samples can even out variability in ex-
cretion over the day, there are also day to day variability which for BPA
may be quite high even when comparing 24-h urine (Lassen et al.,
2013). Also, the relevance of different routes of exposure and the ag-
gregate exposure from them makes the calculation of estimated daily
intakes more challenging (Søeborg et al., 2014). In interpreting the
results of the comparison between model results and measured urinary
concentrations, these uncertainties need to be taken into account.
4.3. Comparison of measured exposure concentrations to BETDI values for
single substances and mixtures
Overall, the BETDI values established with the generic models are
very conservative for TCS, i.e. much lower than the established HBM-I-
values. Whereas for BPA, the values derived with ICF are less con-
servative than the HBM-I-values and the Httk derived values are again
more conservative. It needs to be taken into account that also reference
values established by various authorities might differ substantially,
such as shown in Table 1 as deviations of one order of magnitude,
between TDI and RfD values. Also reference values might be revised
over time, such as observed for BPA during this study.
The results for single substances and mixture risk assessment have
to be interpreted carefully considering the uncertainties discussed
above. The case studies were performed for illustration purpose only.
However, they suggest that the group of phenols (BPA, TCS) are of
higher concern than the other chemicals that were assessed.
5. Conclusions
One strategy to facilitate the use of HBM data in risk assessment is
focused on establishing safe levels in urine or blood against which
measured HBM values can be compared. These safe levels are known as
biomonitoring equivalents (BE) (Hays et al., 2007) or HBM health based
guidance values (Angerer et al., 2011). Since HBM data provide in-
formation on realistic internal co-exposure scenarios for humans, they
are of particular value for assessing risks from combined exposure. The
availability of BE values will facilitate, at screening level, mixture risk
assessments using HBM data. The aim of the study was therefore to
investigate the use of generic PBK models for BE derivation and to il-
lustrate the use of derived values for assessing the risks caused by ex-
posure to multiple chemicals using HBM data.
This study applied two generic PBK models, ICF and Httk, to es-
tablish BE values, using HBM data from a Danish and a Norwegian
cohort study. A limited number of compounds could be simulated, i.e.
four chemicals in ICF and seven chemicals using the seven compart-
mental Httk model. These models were used to assess provisional
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biomonitoring equivalents (BEs), in a forward dosimetry manner, when
applying reference doses (RfDs) or tolerable daily intakes (TDIs).
In the current study, ICF had the advantage of including metabolism
features to address chemicals such as phthalates for which usually
metabolite concentrations are analysed in urine samples. However, the
model seemed to work only for BPA and was less reliable for other
tested chemicals. Furthermore, it required a substantial number of
input parameters which were not easy to find in the literature or si-
mulate, in particular for the metabolites.
The use of Httk is an elegant solution as it has a library of relevant
parameters built into the model covering many chemicals, thus being
very user friendly and limiting the time needed to gather input para-
meters. However, in the current version (1.8, 2018), metabolism is only
addressed via intrinsic clearance. This means that metabolite con-
centration predictions were not included, so that it can only be applied
for chemicals where the parent is measured in the urine samples.
The study shows that establishing safety threshold levels in urine is
a difficult and complex task. There are uncertainties in the simulated
results of metabolite concentrations in urine as well as intraindividual
and interindividual variances that must be taken into account, espe-
cially when based on spot urine samples. Refining the models may re-
duce these uncertainties and improve predictions. However, for certain
chemicals, such as those that mainly remain as a parent compound, it
may be more useful to obtain BE values in blood rather than urine.
The approach described herein is a promising complement to the
current risk assessment procedure for single chemicals and mixtures.
Based on the experience gained with this study, the performance of the
models for other chemicals could be investigated. This will provide
further insight into the uncertainties and their sources, and improve the
accuracy of the simulations.
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